Skip to content Skip to footer
Subscribe Now
NEWS

Atavistik Bio Partners with Pfizer to Discover Novel Precision Allosteric Therapeutics

Shots: Atavistik Bio has signed a research collaboration with Pfizer to discover novel precision allosteric therapies for significant unmet medical needs As per the terms, Atavistik Bio will identify allosteric binders for Pfizer’s 2 undisclosed targets, with Pfizer having the option to license the programs post research. Financial terms are undisclosed The alliance…
January 3, 2025

Read more

NEWS

Pharmanovia Collaborates with Radius Health to Commercialize Abaloparatide for Osteoporosis Treatment

Shots: Pharmanovia has signed an exclusive in-licensing agreement with Radius Health for abaloparatide (US brand name: Tymlos) to treat osteoporosis, expanding its osteoporosis franchise Pharmanovia will handle clinical, regulatory & commercial responsibilities across APAC region (China, Singapore, Thailand, Indonesia, Vietnam, Taiwan, Hong Kong, Malaysia, Macau & Philippines), while Radius will get an upfront, regulatory…
January 3, 2025

Read more

NEWS

The China’s NMPA Grants Approval to Genesis Medtech’s Articulation Powered Stapler, iReach Omnia, for Complex Surgeries

Shots: The NMPA has approved iReach Omnia for market release, enhancing precision and access in complex laparoscopic surgeries The iReach Omnia transforms surgical stapling with 90° articulation, offering precision and maneuverability in confined spaces. It minimizes staple line weak points, reduces anastomotic leakage risks & enhances outcomes in complex procedures like colorectal and thoracic…
January 3, 2025

Read more

NEWS

Hanx Biopharmaceuticals Reports the First Patient Dosing with HX044 in P-I Clinical Evaluation

Shots: Hanx Biopharmaceuticals has dosed the first patient with HX044 under its P-I clinical evaluation for treating solid tumors The dose escalation & expansion P-I/IIa (HX044-I-01) trial will assess safety, tolerability, PK profile & initial efficacy of HX044 for the treatment of advanced solid tumor malignancies HX044 is a first-in-class bispecific antibody and…
January 3, 2025

Read more

NEWS

Chimerix Reports the Dordaviprone’s NDA Submission to the US FDA for Recurrent H3 K27M-Mutant Diffuse Glioma

Shots: Chimerix has submitted the NDA of dordaviprone (small molecule imipridone targeting the mitochondrial protease ClpP & dopamine receptor D2) to the US FDA, seeking accelerated approval for treating recurrent H3 K27M-mutant diffuse glioma Chimerix has also requested priority review along with a Rare Paediatric Disease PRV as a part of submission, as the…
January 2, 2025

Read more

NEWS

MicuRx Pharmaceutical’s MRX-5 Secures the US FDA’s Orphan Drug Designation for Treating NTM Infections

Shots: The US FDA has granted orphan drug designation (ODD) to MRX-5 for treating non-tuberculous mycobacteria (NTM) infections MRX-5 is a new drug for drug-resistant NTM infections, showing strong antibacterial activity, favorable safety & PK profile in both animal studies & human trial. With minimal interactions, low resistance potential & high oral bioavailability, it…
January 2, 2025

Read more

Load more